PRISM BioLab, a Tokyo, Japan-based discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, raised 1.5 Billion Yen ($10.3M) in Series C funding.
The round saw participation from Eli Lilly and Company and Santec Holdings Corporation.
The company intends to use the funds to expand biology and screening capabilities and advance internal pipeline of PPI inhibitors.
Led by CEO Dai Takehara, PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, its technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics.
FinSMEs
26/01/2024